Microsoft's Shopping Spree Isn't Landing Bargains 

The acquisition of Nuance Communications adds to AI capabilities but represents a high price for a struggling business.

Jack Ma's Ant Group Bows to Beijing With Company Overhaul 

Ant Group, the financial-technology giant controlled by billionaire Jack Ma, will apply to become a financial holding company overseen by China's central bank.

Uber Posts Record Demand in March 

Gross bookings for the entire business, which includes rides and food delivery, rose to the highest monthly level in Uber's history as Covid-19 vaccinations pick up.

Cybersecurity Firm Darktrace Targets $4 Billion London IPO 

Darktrace said it aims to go public in London, hoping to cash in on growing demand for its software despite ongoing legal uncertainty over one of its leading backers.

Chip Shortage Is Bad for GM but Worse for Car Buyers 

The shortage of semiconductors is worsening, but might need to drag out indefinitely to have a more noticeable impact on auto stocks.

Boeing Shareholders Will Weigh Need for More Changes to Board 

The plane maker has changed the membership and structure of its board since a second 737 MAX airliner crashed two years ago. Investors will soon decide whether the company has done enough.

Huawei, HSBC Strike Deal Over Documents in Extradition Fight 

Huawei Chief Financial Officer Meng Wanzhou believes the documents will help in her battle against extradition from Canada to the U.S. on charges related to alleged sanctions-busting sales to Iran.

Credit Suisse Faces Tough Choices on Investment Bank 

Credit Suisse's investment bank is the Swiss lender's profit engine. But after the Archegos and Greensill meltdowns, it is expected to be scaled back for safety.

French Firms Reach $15.5 Billion Deal to Create Water, Waste Behemoth 

France's Veolia Environnement agreed to acquire Suez, creating a water and waste-management giant that aims to soak up a global surge in infrastructure and climate-change spending.

Regeneron Drug Stops Symptomatic Covid-19 in Study 

The antibody drug reduced the risk of developing symptomatic Covid-19 infection by 81% compared with a placebo in people living with someone infected by the new coronavirus, a study found.


(END) Dow Jones Newswires

April 12, 2021 13:15 ET (17:15 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.